These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 17417639)

  • 21. ESR1 amplification in breast cancer: controversy resolved?
    Albertson DG
    J Pathol; 2012 May; 227(1):1-3. PubMed ID: 22322671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of estrogen receptor 1 (ESR-1) gene imbalances in colon and hepatocellular carcinomas based on tissue microarrays analysis.
    Tsiambas E; Georgiannos SN; Salemis N; Alexopoulou D; Lambropoulou S; Dimo B; Ioannidis I; Kravvaritis C; Karameris A; Patsouris E; Dourakis S
    Med Oncol; 2011 Dec; 28(4):934-40. PubMed ID: 20458558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
    Gelsomino L; Gu G; Rechoum Y; Beyer AR; Pejerrey SM; Tsimelzon A; Wang T; Huffman K; Ludlow A; Andò S; Fuqua SAW
    Breast Cancer Res Treat; 2016 Jun; 157(2):253-265. PubMed ID: 27178332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.
    Basudan A; Priedigkeit N; Hartmaier RJ; Sokol ES; Bahreini A; Watters RJ; Boisen MM; Bhargava R; Weiss KR; Karsten MM; Denkert C; Blohmer JU; Leone JP; Hamilton RL; Brufsky AM; Elishaev E; Lucas PC; Lee AV; Oesterreich S
    Mol Cancer Res; 2019 Feb; 17(2):457-468. PubMed ID: 30355675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ESR1 gene amplification in breast cancer: a common phenomenon?
    Brown LA; Hoog J; Chin SF; Tao Y; Zayed AA; Chin K; Teschendorff AE; Quackenbush JF; Marioni JC; Leung S; Perou CM; Neilsen TO; Ellis M; Gray JW; Bernard PS; Huntsman DG; Caldas C
    Nat Genet; 2008 Jul; 40(7):806-7; author reply 810-2. PubMed ID: 18583964
    [No Abstract]   [Full Text] [Related]  

  • 27. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conflicting evidence on the frequency of ESR1 amplification in breast cancer.
    Albertson DG
    Nat Genet; 2008 Jul; 40(7):821-2. PubMed ID: 18583976
    [No Abstract]   [Full Text] [Related]  

  • 29. Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate.
    Holst F
    World J Clin Oncol; 2016 Apr; 7(2):160-73. PubMed ID: 27081639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
    Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Harvey V; Neven P; Arnould L; Maibach R; Price KN; Coates AS; Goldhirsch A; Gelber RD; Pagani O; Viale G; Rae JM; Regan MM;
    Breast Cancer Res Treat; 2015 Dec; 154(3):543-55. PubMed ID: 26590813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen receptor (ESR1) mutation in bone metastases from breast cancer.
    Bartels S; Christgen M; Luft A; Persing S; Jödecke K; Lehmann U; Kreipe H
    Mod Pathol; 2018 Jan; 31(1):56-61. PubMed ID: 28799536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.
    Hertz DL; Henry NL; Kidwell KM; Thomas D; Goddard A; Azzouz F; Speth K; Li L; Banerjee M; Thibert JN; Kleer CG; Stearns V; Hayes DF; Skaar TC; Rae JM
    Physiol Genomics; 2016 Sep; 48(9):688-98. PubMed ID: 27542969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors.
    Muthukaruppan A; Lasham A; Woad KJ; Black MA; Blenkiron C; Miller LD; Harris G; McCarthy N; Findlay MP; Shelling AN; Print CG
    Clin Breast Cancer; 2017 Apr; 17(2):139-153. PubMed ID: 27756582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ESR1 gene amplification in endometrial carcinomas: a clinicopathological analysis.
    Rahman MT; Nakayama K; Rahman M; Ishikawa M; Katagiri H; Katagiri A; Ishibashi T; Sato E; Iida K; Ishikawa N; Nakayama N; Miyazaki K
    Anticancer Res; 2013 Sep; 33(9):3775-81. PubMed ID: 24023309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen receptor gene amplification occurs rarely in ovarian cancer.
    Issa RM; Lebeau A; Grob T; Holst F; Moch H; Terracciano L; Choschzick M; Sauter G; Simon R
    Mod Pathol; 2009 Feb; 22(2):191-6. PubMed ID: 18690166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene amplification in ductal carcinoma in situ of the breast.
    Burkhardt L; Grob TJ; Hermann I; Burandt E; Choschzick M; Jänicke F; Müller V; Bokemeyer C; Simon R; Sauter G; Wilczak W; Lebeau A
    Breast Cancer Res Treat; 2010 Oct; 123(3):757-65. PubMed ID: 20033484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
    Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
    Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of ESR1 amplification in a series of breast cancers.
    Adélaïde J; Finetti P; Charafe-Jauffret E; Wicinski J; Jacquemier J; Sotiriou C; Bertucci F; Birnbaum D; Chaffanet M
    Int J Cancer; 2008 Dec; 123(12):2970-2. PubMed ID: 18816632
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen receptor alpha gene polymorphism and breast cancer.
    Siddig A; Mohamed AO; Awad S; Hassan AH; Zilahi E; Al-Haj M; Bernsen R; Adem A
    Ann N Y Acad Sci; 2008 Sep; 1138():95-107. PubMed ID: 18837889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.